Company intelligence / Profile preview
Poplar Therapeutics
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Poplar Therapeutics launched in January 2026 with a $50 million Series A to develop PHB-050, a next-generation anti-IgE antibody designed as an IgE depleter. PHB-050 is currently in Phase 1 clinical trials to evaluate safety, pharmacokinetics, and its ability to reduce IgE levels toward zero. Initial Phase 1 clinical results are expected in the second half of 2026.
- Therapeutic areas
- Rare DiseasesImmunologyDermatology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Poplar Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poplar Therapeutics.